| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10008827 | Annals of Allergy, Asthma & Immunology | 2005 | 8 Pages |
Abstract
To our knowledge, this is the first report of severe visceral granulomatous CVID successfully treated with infliximab. Infliximab may be an effective therapy for granulomas in CVID. Further studies of infliximab and other tumor necrosis factor α antagonist therapies in granulomatous CVID are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Akaluck MD, Sthorn MD, MSc, Andrew J. MD, MSc,